Fasenra

Fasenra contains benralizumab, a monoclonal antibody developed to support people with severe eosinophilic asthma. This therapy is designed to target and reduce eosinophils, a type of white blood cell that plays a major role in airway inflammation and asthma flare-ups. By focusing on this specific pathway, Fasenra helps improve breathing control and reduce the frequency of severe asthma episodes.
Benralizumab works by binding to the interleukin-5 receptor alpha on eosinophils. This action signals the immune system to remove these cells from the bloodstream and airways. As eosinophil levels decrease, inflammation in the lungs is reduced, allowing airways to remain more open and responsive. This targeted approach differentiates Fasenra from broader asthma treatments that act on multiple pathways.
Fasenra is typically used in individuals whose asthma remains difficult to control despite standard inhaled therapies. It is administered at scheduled intervals, and many patients appreciate the less frequent dosing schedule compared with daily asthma management options. Ongoing monitoring by a healthcare professional helps assess response and overall asthma control over time.
Commonly reported side effects may include headache, sore throat, or injection-site reactions. Most effects are mild to moderate, but any new or persistent symptoms should be discussed promptly with a care provider. Because Fasenra influences immune system activity, routine follow-up is important to ensure safety and effectiveness.
Lifestyle factors such as avoiding triggers, maintaining inhaler technique, and following an asthma action plan remain essential. When used as part of a comprehensive asthma strategy, Fasenra offers a focused and innovative option for managing severe eosinophilic asthma and improving quality of life.